Septerna Inc (SEPN) Stock Price, Quote & News

Company Profile

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; a...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 338 3533

Website: septerna.com

Address:

250 East Grand Avenue, South San Francisco, United States

WallStWireAds Jun. 22 at 2:22 PM

$ENTX With Positive FDA Feedback on Phase 3, Entera Bio Just Got the Answer the Market Was Waiting For >> https://www.benzinga.com/content/60014792/positive-fda-feedback-phase-3-entera-bio-just-got-answer-market-was-waiting $LLY $NVOS $SEPN

0 · Reply

WallStWireAds Jun. 22 at 12:31 PM

$ENTX Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis https://www.globenewswire.com/news-release/2026/06/22/3315282/0/en/entera-bio-receives-positive-fda-feedback-on-12-month-registrational-phase-3-study-for-eb613-the-first-oral-anabolic-tablet-in-development-for-postmenopausal-women-with-osteoporosi.html $LLY $SEPN $NVOS

0 · Reply

notreload_ai Jun. 11 at 3:13 PM

Analysts initiate coverage with Buy ratings on $SNSE, $SEPN, $KZIA, $NGEN, and $STRO. https://notreload.xyz/xy/5-hot-biotech-stocks-with-fresh-buy-ratings/

0 · Reply

EMPIR3_37 May. 14 at 8:32 PM

$SEPN Just a matter of time until people find out about this. PTs in the 40s. See ya there

0 · Reply

chole1 Apr. 10 at 7:59 PM

$SEPN High volume sell-off.. hope the Q2 P1 start for the PTH1R is all good.

0 · Reply

SuperGreenToday Apr. 7 at 9:36 PM

$SEPN Share Price: $24.84 Contract Selected: Oct 16, 2026 $32.0 Calls Buy Zone: $6.27 – $7.75 Target Zone: $10.41 – $12.72 Potential Upside: 57% ROI Time to Expiration: 191 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

LovePNW Mar. 11 at 7:50 PM

$SEPN https://www.marketbeat.com/instant-alerts/truist-financial-forecasts-strong-price-appreciation-for-septerna-nasdaqsepn-stock-2026-03-11/

0 · Reply

shavitmi Mar. 6 at 1:57 PM

$TNYA if $ALNY a $40 bilion company works with TNYA i think its a home run $SEPN

0 · Reply

shavitmi Mar. 6 at 11:06 AM

$TNYA the deal with $ALNY remind me the deal $SEPN did with novo

0 · Reply

shavitmi Mar. 5 at 8:26 PM

$TNYA the deal with $ALNY remind me the deal $SEPN did with novo

1 · Reply

Septerna initiated with a Buy at Guggenheim

2026-06-08T12:16:55.000Z - 18 days ago

Septerna to present preclinical characterization of SEP-479

Jun 8, 2026, 8:00 AM EDT - 18 days ago

Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

2026-06-08T10:35:53.000Z - 18 days ago

Septerna price target raised to $53 from $47 at Raymond James

2026-05-26T14:33:56.000Z - 4 weeks ago

3 Unknown Small-Cap Stocks with ‘Strong Buy’ Ratings and Up to 70% Upside in 2026

ANGO KRNT

May 12, 2026, 8:00 PM EDT - 6 weeks ago

Septerna Transcript: Bank of America Global Healthcare Conference 2026

2026-05-11T21:33:42.000Z - 6 weeks ago

Septerna reports Q1 EPS (19c), consensus (27c)

May 11, 2026, 4:01 PM EDT - 6 weeks ago

Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

May 11, 2026, 4:00 PM EDT - 6 weeks ago

Septerna Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 6 weeks ago

Septerna Quarterly report: Q1 2026

May 5, 2026, 8:00 AM EDT - 7 weeks ago

Septerna to Present at Bank of America Securities Health Care Conference

2026-04-30T20:39:44.000Z - 2 months ago

Septerna initiated with a Buy at Stifel

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Septerna Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Septerna Proxy statement: Proxy filing

2026-04-13T12:16:55.000Z - 2 months ago

Septerna doses first patients in SEP-479 trial

Apr 13, 2026, 8:00 AM EDT - 2 months ago

Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

2026-03-24T11:27:17.000Z - 3 months ago

Septerna price target raised to $38 from $34 at JPMorgan

2026-03-11T11:51:58.000Z - 3 months ago

Septerna price target raised to $35 from $34 at Truist

2026-03-10T20:35:29.000Z - 3 months ago

Septerna files automatic mixed securities shelf

2026-03-09T20:40:12.000Z - 3 months ago

Septerna reports Q4 EPS (24c), consensus (22c)

Mar 9, 2026, 4:05 PM EDT - 3 months ago

Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 9, 2026, 9:30 AM EDT - 3 months ago

Septerna Annual report: Q4 2025

Mar 9, 2026, 9:30 AM EDT - 3 months ago

Septerna Earnings release: Q4 2025

Mar 3, 2026, 3:10 PM EST - 4 months ago

Septerna Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 6:00 PM EST - 4 months ago

Septerna Slides: Corporate presentation

2026-03-02T15:10:09.000Z - 4 months ago

Septerna price target raised to $40 from $35 at H.C. Wainwright

Mar 2, 2026, 8:00 AM EST - 4 months ago

Septerna Transcript: Study result

Mar 2, 2026, 8:00 AM EST - 4 months ago

Septerna Press release: Study result

Mar 2, 2026, 8:00 AM EST - 4 months ago

Septerna Slides: Study result

2026-03-01T16:30:07.000Z - 4 months ago

Septerna announces results from Phase 1 trial of SEP-631

Mar 1, 2026, 9:45 AM EST - 4 months ago

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

Feb 24, 2026, 8:00 AM EST - 4 months ago

Septerna to Present at TD Cowen 46th Annual Health Care Conference

Feb 10, 2026, 4:05 PM EST - 4 months ago

Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 10, 2026, 8:00 AM EST - 4 months ago

Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting

2026-01-20T11:20:10.000Z - 5 months ago

Septerna price target raised to $35 from $30 at H.C. Wainwright

Jan 13, 2026, 6:45 PM EST - 5 months ago

Septerna Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 7:00 AM EST - 5 months ago

Septerna Slides: Corporate presentation

2026-01-08T21:16:29.000Z - 6 months ago

Septerna appoints Mark Wilson as chief legal officer

NKTR

Jan 8, 2026, 4:05 PM EST - 6 months ago

Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer

2025-12-23T12:35:16.000Z - 6 months ago

Septerna initiated with a Buy at JonesResearch

2025-12-19T11:30:49.000Z - 6 months ago

Septerna initiated with a Strong Buy at Raymond James

Dec 17, 2025, 8:00 AM EST - 6 months ago

Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference

2025-12-15T11:10:34.000Z - 6 months ago

Septerna initiated with a Buy at Truist

Dec 2, 2025, 10:25 AM EST - 7 months ago

Septerna Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 25, 2025, 8:00 AM EST - 7 months ago

Septerna to Participate in 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 4:00 PM EST - 8 months ago

Septerna Transcript: TD Cowen Immunology and Inflammation Summit

Nov 10, 2025, 4:00 PM EST - 8 months ago

Septerna Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:30 AM EST - 8 months ago

Septerna Earnings release: Q3 2025

Nov 10, 2025, 8:30 AM EST - 8 months ago

Septerna Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 8 months ago

Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 8:00 AM EST - 8 months ago

Septerna to Participate in Upcoming Investor Conferences

Sep 29, 2025, 4:01 PM EDT - 9 months ago

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

Sep 5, 2025, 8:45 AM EDT - 10 months ago

Septerna Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 11:30 AM EDT - 10 months ago

Septerna Transcript: Cantor Global Healthcare Conference 2025

Aug 21, 2025, 8:00 AM EDT - 11 months ago

Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases

Aug 11, 2025, 4:01 PM EDT - 11 months ago

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:00 PM EDT - 11 months ago

Septerna Quarterly report: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 11 months ago

Septerna Earnings release: Q2 2025

Jun 5, 2025, 3:45 PM EDT - 1 year ago

Septerna Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Septerna to Present at Jefferies Global Healthcare Conference

May 15, 2025, 4:01 PM EDT - 1 year ago

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

May 14, 2025, 6:00 PM EDT - 1 year ago

Septerna Earnings release: Q1 2025

May 14, 2025, 6:00 PM EDT - 1 year ago

Septerna Quarterly report: Q1 2025

May 14, 2025, 7:31 AM EDT - 1 year ago

Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases

NVO

May 14, 2025, 7:04 AM EDT - 1 year ago

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

NVO

May 14, 2025, 6:59 AM EDT - 1 year ago

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Septerna Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Septerna Proxy statement: Proxy Filing

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Septerna Annual report: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Septerna Earnings release: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Septerna to Present at TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 4:15 PM EST - 1 year ago

Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm

Feb 18, 2025, 8:00 AM EST - 1 year ago

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Jan 14, 2025, 6:45 PM EST - 1 year ago

Septerna Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 6:45 PM EST - 1 year ago

Septerna Slides: FY 2025

Dec 18, 2024, 8:00 AM EST - 1 year ago

Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 20, 2024, 7:00 AM EST - 1 year ago

Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 19, 2024, 6:00 PM EST - 1 year ago

Septerna Quarterly report: Q3 2024

Nov 19, 2024, 6:00 PM EST - 1 year ago

Septerna Earnings release: Q3 2024

Oct 30, 2024, 4:41 PM EDT - 1 year ago

Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering

Oct 25, 2024, 12:25 PM EDT - 1 year ago

Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut

Oct 24, 2024, 9:47 PM EDT - 1 year ago

Septerna Prices Upsized Initial Public Offering

Oct 24, 2024, 8:11 AM EDT - 1 year ago

Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO

WallStWireAds Jun. 22 at 2:22 PM

0 · Reply

WallStWireAds Jun. 22 at 12:31 PM

0 · Reply

notreload_ai Jun. 11 at 3:13 PM

Analysts initiate coverage with Buy ratings on $SNSE, $SEPN, $KZIA, $NGEN, and $STRO. https://notreload.xyz/xy/5-hot-biotech-stocks-with-fresh-buy-ratings/

0 · Reply

EMPIR3_37 May. 14 at 8:32 PM

$SEPN Just a matter of time until people find out about this. PTs in the 40s. See ya there

0 · Reply

chole1 Apr. 10 at 7:59 PM

$SEPN High volume sell-off.. hope the Q2 P1 start for the PTH1R is all good.

0 · Reply

SuperGreenToday Apr. 7 at 9:36 PM

0 · Reply

LovePNW Mar. 11 at 7:50 PM

$SEPN https://www.marketbeat.com/instant-alerts/truist-financial-forecasts-strong-price-appreciation-for-septerna-nasdaqsepn-stock-2026-03-11/

0 · Reply

shavitmi Mar. 6 at 1:57 PM

$TNYA if $ALNY a $40 bilion company works with TNYA i think its a home run $SEPN

0 · Reply

shavitmi Mar. 6 at 11:06 AM

$TNYA the deal with $ALNY remind me the deal $SEPN did with novo

0 · Reply

shavitmi Mar. 5 at 8:26 PM

$TNYA the deal with $ALNY remind me the deal $SEPN did with novo

1 · Reply

LovePNW Mar. 3 at 9:14 PM

$SEPN https://www.marketbeat.com/instant-alerts/wells-fargo-company-increases-septerna-nasdaqsepn-price-target-to-4800-2026-03-03/

0 · Reply

IN0V8 Mar. 3 at 8:55 PM

$SEPN Buy Wells Fargo raises target price to $48 from $28

0 · Reply

AlertsAndNews Mar. 1 at 11:32 PM

$SEPN Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy "SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses Studied with an Adverse Event Profile Comparable to Placebo; Pharmacokinetic Profile Supports Once-Daily Oral Dosing" Conference call here tomorrow morning as well. "Company to Host Conference Call and Webcast on Monday, March 2, 2026, at 8:00 a.m. ET"

0 · Reply

BillionerOfKing Feb. 25 at 10:54 PM

$SEPN Current Stock Price: $29.99 Contracts to trade: $30.0 SEPN Mar 20 2026 Call Entry: $1.85 Exit: $3.42 ROI: 85% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

RaymondNorman877 Feb. 18 at 12:40 PM

$SEPN Rare-disease biotech with asymmetric upside; timeline slippage is main threat.

0 · Reply

BondHarbinger Feb. 4 at 2:24 PM

$SEPN is a clinical-stage biotech focused on rare diseases; its pipeline is in development, making it a high-risk, binary investment.

0 · Reply

BillionerOfKing Feb. 3 at 2:10 AM

$SEPN Current Stock Price: $25.09 Contracts to trade: $26.0 SEPN Feb 20 2026 Call Entry: $0.85 Exit: $1.52 ROI: 79% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Market Cap	1.56B
Revenue (ttm)	45.95M
Net Income (ttm)	-48.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-106.38%
Debt to Equity Ratio	0.00

Volume	1,480,100
Avg Vol	359,924
Day's Range	N/A - N/A
Shares Out	45.08M
Stochastic %K	84%
Beta	2.39
Analysts	Strong Sell
Price Target	$45.78